CEFONICID TEVA

Country: Ísrael

Tungumál: enska

Heimild: Ministry of Health

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
18-08-2016

Virkt innihaldsefni:

CEFONICIDE AS SODIUM

Fáanlegur frá:

SALOMON,LEVIN & ELSTEIN LTD

ATC númer:

J01DC06

Lyfjaform:

POWDER FOR SOLUTION FOR INJECTION

Samsetning:

CEFONICIDE AS SODIUM 1000 MG/VIAL

Stjórnsýsluleið:

I.M, I.V

Gerð lyfseðils:

Required

Framleitt af:

LABORATORIO FARMACEUTICO C.T. S.R.L., ITALY

Meðferðarhópur:

CEFONICIDE

Lækningarsvæði:

CEFONICIDE

Ábendingar:

Treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. Studies on specimens obtained prior to therapy should be used to determine the susceptibility or the causative organisms to Cefonicid.Therapy with Cefonicid may be initiated pending results of the studies however.Treatment should be adjusted according to study findings. Cefonicid-teva is indicated in the treatment of the infections of the lower respiratory tract urinary tract skin and skin structure bone and joints. In the treatment of the above-mentioned infections the product is particularly used in weak and/or immuno-depressed patients. Surgical prophylaxis: The administration of a single 1 g. dose of Cefonicid-teva before surgery may reduce the incidence of post-operative infections caused by susceptible microorganisms in patients undergoing surgical procedures classified as contaminated or potentially contaminated or in patients in whom infection at the operative site would present a serious risk providi

Leyfisdagur:

2010-04-30

Vara einkenni

                                Cefonicid-Teva 14. 2. 2008 , RH
"
ע עבקנ הז ןולע טמרופ
"
רשואו קדבנ ונכותו תואירבה דרשמ י
."
רשואמ ןולע
:
ראורבפ
2008
“This leaflet format has been determined by the Ministry of Health
and the content thereof
has been checked and approved.” Date of approval: February 2008.
אפורל ןולע
Physician's Package Insert
=============================================================
דיצינופצ
עבט
®
CEFONICID TEVA
®
- ---------- ---- ---------- ---- ---------- ---- ---------- ----
---------- ---- ---------- ---- ----------
רירשה וא דירוה ךותל הקרזהל
POWDER FOR INJECTION
COMPOSITION
Each vial contains:
_Active Ingredient _
Cefonicid sodium
1.081 g
Equivalent to cefonicid
1 g
As powder for injectable solution.
MECHANISM OF ACTION
_Pharmacodynamics _
Cefonicid is a semi-synthetic broad-spectrum cephalosporin antibiotic
resistant to
beta-lactamases. Similarly to other cephalosporins, cefonicid exerts
its antibacterial
activity through the inhibition of the bacterial cell-wall synthesis.
Its _ in vitro _ and _ in vivo _ activity against a wide range of
Gram-positive and Gram-
negative microorganisms is documented
_Pharmacokinetics _
Following
administration
of
therapeutic
doses
(1
g)
of
cefonicid
to
healthy
volunteers,
high
serum
concentrations
are
achieved
(about
100
micrograms/ml
following each I.M. administration), over a prolonged period of time.
The half-life of
cefonicid following I.V. and I.M. administration is 4.5 hours.
Cefonicid is highly and
reversibly protein-bound.
Cefonicid is not metabolized. 99% is excreted unchanged in the urine
in 24
hours. A 500 mg I.M. dose provides a high urinary concentration (384
microgram/ml)
at 6-8 hours. Cefonicid reaches therapeutic concentrations in the
following tissues
and fluids: heart, bones, biliary tract, prostate, uterus, adipose
tissue, blood, urine,
bile, and in purulent and surgical wounds. Cefonicid is not indicated
for the treatment
of meningitis since it does not cross t
                                
                                Lestu allt skjalið
                                
                            

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu